Stock Events

Stock Events

Moleculin Biotech 

$0.7099
88
+$0.03+5.09% Friday 20:00
-$0.01-0.7%Friday 23:15After hours

Statistics

Day High
0.7198
Day Low
0.7
52W High
15.75
52W Low
0.161
Volume
7,278
Avg. Volume
-
Mkt Cap
13.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-17.02
-11.26
-5.51
0.25
Expected EPS
-0.443333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-33.66MNet Income

Analyst Ratings

3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBRX. It's not an investment recommendation.
NVIDIA
14
NVDA
Apple
12
AAPL
AMD
11
AMD
Realty Income
10
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Moleculin, including cancer, making it a direct competitor.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for cancer, which competes with Moleculin's cancer drug development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Moleculin's oncology focus.
Merck
MRK
Mkt Cap366B
Merck operates in the pharmaceutical industry with a strong emphasis on cancer drugs, competing with Moleculin's product pipeline.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global biopharmaceutical company with a broad range of drugs, including cancer treatments that compete with Moleculin's developments.
Novartis
NVS
Mkt Cap292.35B
Novartis is a healthcare company that offers treatments for a variety of conditions, including cancer, making it a competitor to Moleculin.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, directly competing with Moleculin's focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a global healthcare leader that develops drugs for cancer among other diseases, positioning it as a competitor to Moleculin.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a significant focus on oncology, competing with Moleculin.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative medicines and therapeutic advancements, including in oncology, making it a competitor to Moleculin.

About

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Show more...
CEO
Walter V. Klemp
Employees
17
Country
United States
ISIN
US60855D4088
WKN
000A41SET

Listings

STU
DE
MOL.STU
LSE
GB
0K2H.LSE
MU
DE
MOL0.MU
BOATS
BOATS
MBRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Moleculin Biotech stock price today?▼
The current price of MBRX is $0.71 USD — it has increased by +5.09% in the past 24 hours. Watch Moleculin Biotech stock price performance more closely on the chart.
What is Moleculin Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Moleculin Biotech stocks are traded under the ticker MBRX.
Is Moleculin Biotech stock price growing?▼
MBRX stock has risen by +9.23% compared to the previous week, the month change is a +82.03% rise, over the last year Moleculin Biotech has showed a -92.43% decrease.
What is Moleculin Biotech market cap?▼
Today Moleculin Biotech has the market capitalization of 13.83M
When is the next Moleculin Biotech earnings date?▼
Moleculin Biotech is going to release the next earnings report on November 09, 2026.
What were Moleculin Biotech earnings last quarter?▼
MBRX earnings for the last quarter are -1.4 USD per share, whereas the estimation was -1.55 USD resulting in a +9.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Moleculin Biotech revenue for the last year?▼
Moleculin Biotech revenue for the last year amounts to 0 USD.
What is Moleculin Biotech net income for the last year?▼
MBRX net income for the last year is -33.66M USD.
How many employees does Moleculin Biotech have?▼
As of September 05, 2026, the company has 17 employees.
In which sector is Moleculin Biotech located?▼
Moleculin Biotech operates in the Health & Wellness sector.
When did Moleculin Biotech complete a stock split?▼
The last stock split for Moleculin Biotech was on December 01, 2025 with a ratio of 1:25.
Where is Moleculin Biotech headquartered?▼
Moleculin Biotech is headquartered in HOUSTON, United States.